Generics overtake new drugs in EU centralised procedure
This article was originally published in Scrip
One of the most striking statistics in the European Medicines Agency's first monthly report on the centralised approvals procedure is that generics have for the first time overtaken new products in terms of the number of applications for marketing authorisations dealt with by the agency. The report also reveals a sharp increase in the EMA's overall evaluation workload.
You may also be interested in...
The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.